EU Clinical Trial 2018-003096-35

Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant  May 23, 2019

Main objective of the trial: • To assess the efficacy of relacorilant for the treatment of endogenous Cushing syndrome based on glycemic control and BP control during the Randomized-Withdrawal (RW) phase • To assess the safety of relacorilant for the treatment of endogenous Cushing syndrome • Evaluar la eficacia de relacorilant para el tratamiento del síndrome de Cushing endógeno basándose en el control glucémico y de la presión arterial (PA) durante la fase de retirada aleatorizada (RA) • Evaluar la seguridad de relacorilant para el tratamiento del síndrome de Cushing endógeno

Parties

Sponsors
Countries
AT BG CA DE ES IL IT NL PL US
Keywords
CORT125134 Cushings syndrome Relacorilant

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.